Neogenomics vs 10x Genomics
Neogenomics and 10x Genomics are similar in size: $727m and $643m of revenue in their latest fiscal years. Neogenomics grew faster (10.1% against 5.2%). 10x Genomics kept more of each dollar of sales as profit: a net margin of -6.8% against -14.9%.
| Latest fiscal year | NeogenomicsNEO, 2025 | 10x GenomicsTXG, 2025 |
|---|---|---|
| Revenue | $727m | $643m |
| Revenue growth | 10.1% | 5.2% |
| Net income | −$108m | −$43.5m |
| Operating margin | — | -9.5% |
| Net margin | -14.9% | -6.8% |
| Return on equity | -12.4% | -5.8% |
| Free cash flow | −$21.8m | $130m |
| Cash | $160m | $474m |
| Total debt | $345m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,500 | — |
| Market value | $2.20bn | $8.34bn |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | 33 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 50 sales |